JLE

Innovations & Thérapeutiques en Oncologie

MENU

Colorectal cancer: from molecular to clinical consensus? Volume 5, issue 1, January-February 2019

Figures


  • Figure 1
Authors
1 Laboratoire de médecine personnalisée, pharmacogénomique et optimisation thérapeutique (UMR-S1147)
Université Paris Descartes, Sorbonne Paris Cité
45, rue des Saints-Pères
75006 Paris
France
2 INSERM Paris France
3 Hôpital Européen Georges Pompidou Pôle de Biologie
Paris
France
* Tirés à part

Colon cancers are a very heterogeneous group of diseases. An international consortium has recently established a consensual transcriptomic classification allowing the categorization of tumors into four robust subtypes (“consensus molecular subtypes”, CMS), designated CMS1, CMS2, CMS3 and CMS4, associated with a prognostic value. Depending on the molecular classification, different treatments may be proposed, such as immunotherapy for MSI tumors belonging to the CMS1 group and anti-EGFR antibodies for the RAS wild-type tumors from CMS2 group. However, the identification of potential therapeutic targets is still needed for RAS-mutated tumors (CMS3) and the poor predictive group CMS4. The CMS classification is a tool of choice for the stratification of colon cancers and the identification of homogeneous subtypes with prognostic and sometimes predictive value of therapeutic efficacy.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License